Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05152173 · ClinicalTrials.gov registry record · Phase 2
Efficacy, Safety, and Tolerability, of EN3835 vs Placebo in the Treatment of Plantar Fibromatosis
A Phase 2 study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 176
- Enrollment target
NCT05152173: Completed Phase 2 study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
NCT05152173 is a Phase 2 study that has completed, run by Endo USA Inc., a Keenova Therapeutics Company. The registered enrollment target is 176 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05152173, a Phase 2 study, has completed, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 176 participants
- Enrollment target
Study Summary
This randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of up to 2 treatments of EN3835 vs placebo in participants with plantar fibromatosis.
Interventions
- OTHER Placebo
- BIOLOGICAL EN3835
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 176 participants |
| Start Date | 2021-11-29 |
| Est. Completion | 2023-01-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05152173
The ClinicalTrials.gov registry entry for NCT05152173 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 176 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Endo USA Inc., a Keenova Therapeutics Company, which has 61 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05152173 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05152173 about?
NCT05152173 is a clinical study titled "Efficacy, Safety, and Tolerability, of EN3835 vs Placebo in the Treatment of Plantar Fibromatosis". This randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of up to 2 treatments of EN3835 vs placebo in participants with plantar fibromatosis.
What is the current status of trial NCT05152173?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 176 participants. The study started on 2021-11-29. Estimated completion is 2023-01-10.
What interventions are being tested in trial NCT05152173?
The interventions under investigation include: Placebo (OTHER), EN3835 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05152173?
This trial is sponsored by Endo USA Inc., a Keenova Therapeutics Company, which has 61 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.